Blog

S&U (LSE:SUS) reported revenue of £57.3 million for the interim period, an increase of 11% year on year, while profit before tax was broadly unchanged at £15.7 million.

Basic earnings per share increased to 96.8 pence, while net receivables rose to £541.0 million. The increase in receivables was funded partly through higher borrowings, with group gearing reaching 114%.

The specialist finance group increased its first interim dividend to 36 pence per share.

Advantage Finance Profit Rises to £11.8 Million

S&U’s Advantage Finance motor lending division reported profit before tax of £11.8 million.

The company attributed the performance to increased advances, improved customer repayments and lower impairment charges.

Advantage Finance has also introduced changes to its credit scoring processes and is using AI-enabled technology within its customer service operations.

The division provides finance primarily for used vehicle purchases in the UK.

Aspen Bridging Reports £4 Million Profit

Aspen Bridging, S&U’s property finance business, reported profit of £4.0 million during the period.

The division increased its receivables and continued to shift its lending mix towards longer-duration loans.

S&U said Aspen experienced pressure on margins and higher impairment charges during the period, against a backdrop of subdued activity in the UK housing market and economic and regulatory uncertainty.

S&U Progresses £600 Million Securitisation Facility

The group continued to expand its net receivables and said legal work on a new £600 million three-year securitisation facility was substantially complete.

The planned facility is intended to diversify the group’s sources of funding as its lending operations expand.

Management also highlighted ongoing regulatory developments affecting motor finance and the broader financial services sector.

S&U noted proposed changes concerning regulatory costs and the respective roles of the Financial Conduct Authority and Financial Ombudsman Service, although the eventual impact of these measures remains dependent on their final implementation.

More About S&U

S&U plc is a UK specialist finance company operating through Advantage Finance and Aspen Bridging.

Advantage Finance provides used vehicle financing, while Aspen Bridging provides property bridging and buy-to-let lending. The group funds its lending activities through a combination of borrowing and securitisation facilities.

Atome PLC (LSE:ATOM) said publication of its audited financial statements for the year ended 31 December 2025 and unaudited interim results for the six months ended 30 June 2026 has been delayed further.

The company now expects to publish both sets of financial results on 2 October 2026, compared with its previously indicated deadline of 30 September.

Atome’s shares will remain suspended from trading on AIM until the financial statements are published.

The company did not provide additional financial information or further details regarding the results in the supplied update.

More About Atome

Atome PLC is an AIM-listed company operating in the energy sector under the ticker ATOM.

As an AIM-listed company, Atome is subject to the market’s reporting requirements, including requirements relating to the publication of annual and interim financial statements.

The company’s advisers include Beaumont Cornish as nominated adviser, SP Angel as broker and FTI Consulting for communications.

MicroSalt (LSE:SALT) reported unaudited revenue of US$1.4 million for the first half of 2026, an increase of 67% from the same period a year earlier, supported by increased business-to-business sales to food manufacturers.

Gross margin increased to 12%, while the company’s net loss narrowed to US$1.5 million.

MicroSalt said it expanded its customer base during the period and secured approved supplier status with FMCG and ingredient companies as it continued the commercial rollout of its low-sodium salt technology.

The company said products using its technology accounted for approximately 1.4 billion servings during the period.

MicroSalt Targets US$4.5 Million FY26 Revenue

MicroSalt said its sales pipeline includes advanced discussions with a customer that, if converted into sales as anticipated, could contribute towards full-year 2026 revenue of US$4.5 million.

The company is also targeting US$15 million in sales for FY27. Both figures represent management targets and remain dependent on the progression of customer discussions and product rollouts.

MicroSalt is increasing its focus on bulk B2B sales as food manufacturers evaluate and introduce its technology into their products.

Equity Raise Adds to Funding

Following the end of the reporting period, MicroSalt completed an oversubscribed equity fundraising and converted the majority of its convertible debt.

The company said these measures strengthened its balance sheet and provided additional funding as it works towards its objective of reaching cash-flow breakeven.

MicroSalt is also developing additional products, including MicroSalt Premium and MicroSalt Fibre, as it seeks to expand the applications and markets for its technology.

More About MicroSalt

MicroSalt plc is an AIM-listed company developing and commercialising low-sodium salt products for food manufacturers and consumers.

The company’s technology uses micron-sized salt particles and is designed to provide equivalent salt taste with approximately 50% less sodium.

MicroSalt has been operational since 2018 and holds a granted US patent alongside additional patent applications in other jurisdictions. Its products are marketed through B2B food manufacturing and consumer channels.

Braemar (LSE:BMS) reported revenue of £74.3 million for the six months ended 31 August 2026, an increase of 16%, supported by the shipping rate environment during the period.

Underlying operating profit increased 7% to £6.0 million after £1.4 million of investment related to the group’s growth strategy.

Braemar reduced net debt to zero during the first half and reported a forward order book of $73.4 million.

The company said it remains confident of meeting market expectations for the full financial year.

Braemar Invests in Expansion

During the period, Braemar continued to invest in its operations, including through senior appointments and the establishment of a new power desk.

The company expects these investments to contribute to profit growth during the second half of the financial year.

Braemar provides chartering, advisory and risk management services to customers across global shipping and energy markets.

Group Targets £200 Million Revenue by FY30

Management reiterated its strategic target of developing Braemar into a business generating £200 million of annual revenue by FY30.

The target remains a company objective and will depend on the execution of its growth strategy over the coming years.

Braemar said its balance sheet and ongoing investments provide a platform for pursuing its expansion plans while continuing to serve customers across its shipping and energy markets.

More About Braemar

Braemar Plc is a London-listed provider of chartering, investment and risk management advisory services to the global shipping and energy industries.

The group employs brokers and other specialist professionals who provide services to customers operating across maritime and energy markets. Braemar has traded on the London Stock Exchange under the symbol BMS since 1997.

Wilmington (LSE:WIL) reported ongoing revenue of £120.0 million for the year ended 30 June 2026, an increase of 37%, as eight of its nine ongoing businesses recorded growth.

Ongoing adjusted EBITA increased 33% during the year, while ongoing adjusted profit before tax rose 15% to £30.1 million. Total adjusted profit before tax was £31.4 million.

The company said annual recurring revenue increased 6% and represented 38% of organic revenue, while repeat revenue accounted for 80%.

Wilmington said total adjusted profit before tax has recorded a compound annual growth rate of 13% over the past six years.

Dividend Increased to 12.5 Pence

Wilmington increased its total dividend for the year by 9% to 12.5 pence per share.

The group reported net debt equivalent to 1.7 times total adjusted EBITDA following investment and acquisition activity during the year.

Conversia Acquisition Expands Data Privacy Operations

During the year, Wilmington completed the £105.2 million acquisition of Spanish data privacy specialist Conversia.

The acquisition expanded the group’s operations in international Governance, Risk and Compliance, or GRC, markets and increased the proportion of recurring revenue within the business.

Wilmington said Conversia is trading ahead of its expectations.

The company continues to expect its overall business to meet market forecasts for the current financial year.

Wilmington Continues RegTech Investment

Wilmington continued to invest in its AI-enabled RegTech platform during the period, including tools used within its regulatory information and education services.

The company said the technology is being deployed to support learner engagement and improve internal efficiency.

Management identified increasing regulatory requirements, ESG-related compliance and the adoption of technology-based compliance tools as factors affecting demand across its markets.

More About Wilmington

Wilmington plc is an international Governance, Risk and Compliance RegTech services group listed on the London Stock Exchange’s Main Market.

The group provides regulatory learning and training, regulatory intelligence and data services across areas including health, safety and ESG, legal services, data privacy and financial services.

Wilmington employs more than 1,100 people and provides services to customers in approximately 120 countries.

GENinCode (LSE:GENI) reported revenue of £1.1 million for the six months ended 30 June 2026, compared with £1.6 million a year earlier, as the company continued the development and commercial rollout of its cardiovascular and ovarian cancer risk assessment products.

The company attributed the decline in revenue to NHS spending reductions and the absence of income generated by a Catalonia pilot programme in the comparable period.

Adjusted EBITDA loss narrowed to £2.26 million, supported by cost reductions and favourable foreign exchange movements.

GENinCode completed a placing in February that increased its cash resources to £2.0 million. The company said the funding is expected to provide a cash runway into the first quarter of 2027.

CARDIO inCode-Score Advances Towards US and EU Regulatory Filings

During the period, GENinCode completed manufacturing and clinical validation of CARDIO inCode-Score, its polygenic risk test for coronary artery disease, in collaboration with Thermo Fisher Scientific.

The company is preparing to distribute the test through reference laboratory networks in the US and European Union.

GENinCode expects to submit a De Novo application for CARDIO inCode-Score to the US Food and Drug Administration in November 2026, followed by an EU IVDR filing in December.

The company also noted updated ACC/AHA guidelines recognising coronary artery disease polygenic risk scores as a genetic risk enhancer.

Spanish Pilot Programmes Move Towards Wider Rollout

Pilot implementations of CARDIO inCode-Score in Catalonia and Extremadura have been completed, with GENinCode working towards broader clinical adoption in Spain.

Following the reporting period, data from the Catalonia programme were presented at the ESC Congress in Munich. According to the company, the results showed reductions in cardiovascular risk and changes in clinical measures including lower LDL cholesterol and increased smoking abstinence.

GENinCode expects the full results to be published during the first half of 2027.

ROCA Funding Extended Through 2027

The company’s ROCA algorithm, which assesses ovarian cancer risk, secured an extension of NHS and University College London Hospitals funding through 2027.

GENinCode plans to pursue further adoption of ROCA across NHS trusts and regional expansion of the programme.

The company is also working to increase adoption of its LIPID inCode and CARDIO inCode-Score products in the US, while progressing cardiovascular testing programmes in other markets including Spain and Mexico.

GENinCode Forecasts 2026 Revenue of Around £3.2 Million

GENinCode now expects full-year 2026 revenue of approximately £3.2 million, reflecting slower-than-expected uptake through Thermo Fisher and lower NHS sales.

The company expects adjusted EBITDA to improve further as previously implemented cost reductions take effect and additional commercial channels develop.

Priorities for the remainder of 2026 include expanding CARDIO inCode-Score with Thermo Fisher, increasing adoption of LIPID inCode in the EU and US, progressing clinical adoption in Spain and Mexico, and expanding the use of ROCA within the NHS.

More About GENinCode

GENinCode Plc is a UK-based predictive genetics company developing genetic risk assessment products for cardiovascular disease and ovarian cancer surveillance.

The company develops in vitro diagnostic molecular tests combining clinical algorithms, bioinformatics and polygenic risk scoring and operates through businesses in the UK, Europe and the US.

NIOX Group (LSE:NIOX) reported revenue of £24.0 million for the first half of 2026, compared with £25.2 million a year earlier, as lower research sales offset growth in its clinical business.

Clinical revenue increased 3% to £20.6 million, while the group’s gross margin rose to 71%. Adjusted EBITDA declined to £8.3 million.

The company said its results reflected continued consumables revenue and cost controls alongside investment in its US commercial operations and product development.

NIOX PRO Receives European and UK Regulatory Approvals

During the period, NIOX received CE Mark and UK MHRA approval for its NIOX PRO device and transitioned from its existing NIOX VERO platform without supply disruption.

The company also entered into a 10-year exclusive sensor supply agreement intended to support the manufacture of its FeNO testing products.

In the US, NIOX completed the deployment of its field sales team as part of its commercial expansion plans. Development work also continued on MyNO, the company’s planned home-use device.

Americas Clinical Sales Increase

Clinical sales in the Americas increased 6% on a constant currency basis during the first half.

Sales in the APAC and EMEA regions declined slightly. NIOX attributed the regional performance to factors including lower reimbursement in China, competition from lower-cost products and orders deferred pending regulatory approvals for NIOX PRO.

Management expects some of these factors to ease as the new product approvals take effect and deferred demand moves into the second half.

NIOX Launches £12.5 Million Share Tender Offer

NIOX paid a £6.5 million final dividend for 2025 and subsequently launched a tender offer to repurchase up to 15,625,000 shares at 80 pence per share.

If completed in full, the tender would return a further £12.5 million to shareholders. The company said this would take total shareholder distributions over four years to approximately £60 million.

NIOX estimated that its pro forma cash balance would be approximately £5 million following completion of the tender offer.

More About NIOX Group

NIOX Group plc is a UK-based medical device company specialising in fractional exhaled nitric oxide, or FeNO, testing used in the diagnosis, monitoring and management of respiratory conditions including asthma and chronic obstructive pulmonary disease.

The company develops and sells FeNO measurement devices and associated consumables through direct sales channels and distributors in more than 50 countries. Its products are used in clinical settings and by pharmaceutical companies and contract research organisations conducting respiratory clinical trials.

Tekmar Group plc (LSE:TGP) has secured a €6 million contract extension for a European offshore wind project and a £4 million working capital facility as the group reported higher second-half revenue for FY26.

The company said revenue during the second half of FY26 was higher than both the first half and the comparable period in 2025, supported by increased manufacturing activity in the UK and a greater proportion of European offshore renewables work in its order book.

Tekmar expects full-year FY26 revenue to be more than 20% higher than in FY25. However, the company said growth in adjusted EBITDA is expected to be limited by a slower-than-anticipated increase in volumes, disruption related to conflict in the Middle East and UK supply chain issues.

European Offshore Wind Contract Extended by €6 Million

Tekmar has secured a €6 million extension to an existing European offshore wind contract covering the supply of cable protection systems and associated engineering services.

The work will be delivered from the group’s manufacturing facility in Newton Aycliffe, UK.

The company said the contract contributes to a shift in its order book towards European offshore renewables and forms part of its Project Aurora strategy, which includes increasing customer engagement and improving utilisation of its UK manufacturing capacity.

Tekmar expects its opening order book for FY27 to be more than 50% higher than it was at the beginning of FY26.

Tekmar Secures £4 Million Working Capital Facility

The group has also secured a £4 million working capital facility intended to support the execution of larger projects in the European offshore wind market.

Tekmar said the facility follows previous balance sheet measures and will provide additional working capital as it delivers its order book.

More About Tekmar Group

Tekmar Group plc is a UK-headquartered provider of asset protection technology and offshore energy services serving offshore wind, subsea interconnector, oil and gas, and marine infrastructure projects.

The group operates through its Asset Protection Technology and Offshore Energy Services divisions, providing products and engineering services including cable protection and subsea stabilisation systems.

Tekmar has worked on more than 120 offshore wind projects across 25 countries, representing more than 50GW of installed capacity, according to the company.

Talon Resources (LSE:TAR) has completed the acquisition of a 90% interest in the Eagle Lake gold project and started a maiden drilling programme following its admission to AIM and a fundraising of approximately £2.0 million.

The company cancelled its listing on the Main Market and commenced trading on AIM as it shifted its focus towards gold exploration in North America.

Phase 1 exploration at Eagle Lake, located in Ontario’s Wabigoon Subprovince, confirmed gold mineralisation across several targets and identified the new Moss Knoll prospect.

Following the initial exploration work, Talon expanded its maiden drilling programme to approximately 1,375 metres. Results from the programme will be used to inform the company’s planned Phase 2 exploration activities.

Talon is also using data-driven targeting through its partnership with MINML as part of its exploration programme and is evaluating additional opportunities in the Wabigoon Subprovince and elsewhere in North America.

Talon Reports £729,808 First-Half Pre-Tax Loss

Talon reported a pre-tax loss of £729,808 for the half-year, with administrative costs increasing in connection with the Eagle Lake transaction and the expansion of its exploration activities.

The company raised approximately £2.0 million through a placing and subscription, with the proceeds allocated to exploration at Eagle Lake and general working capital.

Talon said its available resources include cash and receivables relating to share subscriptions as it progresses the drilling programme.

More About Talon Resources

Talon Resources plc is a North American gold exploration company focused on the Eagle Lake project in Ontario’s Wabigoon Subprovince.

The company trades on AIM under the ticker TAR and is seeking to develop a broader portfolio of exploration assets in North America. It also works with MINML to apply machine-learning tools to geological targeting.